Area:
Biochemistry, Molecular Biology, Cell Biology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Andrew Koff is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
1992 — 1993 |
Koff, Andrew |
F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Regulation of Cyclin E Kinase and Its Role in Dna Replic @ Fred Hutchinson Cancer Research Center
cell cycle proteins; phosphotransferases; DNA replication; simian virus 40; phosphorylation;
|
0.904 |
1995 |
Koff, Andrew |
R55Activity Code Description: Undocumented code - click on the grant title for more information. |
Regulation of P27kipi and Its Role in G1 Progression @ Sloan-Kettering Institute For Cancer Res
This is a Shannon Award providing partial support for the research projects that fall short of the assigned institute's funding range but are in the margin of excellence. The Shannon Award is intended to provide support to test the feasibility of the approach; develop further tests and refine research techniques; perform secondary analysis of available data sets; or conduct discrete projects that can demonstrate the PI's research capabilities or lend additional weight to an already meritorious application. The abstract below is taken from the original document submitted by the principal investigator. Kinase inhibitory proteins, KIPs, negatively regulate the activity of the G1-cyclin/cyclin-dependent kinase (CDK) complexes in response to signals that arrest cell proliferation. We have recently discovered that p27KIP1 negatively regulates cyclin E associated kinase activity in response to TGFbeta-treatment or density dependent inhibition of growth. In addition, p27KIP1 activity can also associate with cyclin D-associated kinases. Because p27KIP1 is present, but inactive, in proliferating cells it may have a role in regulating G1 progression. Two models have been proposed to explain this role in G1 progression. Model 1 places P27KIP1 in a role where it sets the threshold level of G1- cyclin accumulation necessary to allow a cell to enter into S-phase. Model 2 supposes that p27KIP1 may constrain the activation of cyclin E- associated kinase in the absence of the cyclin D-associated kinase. The current data available supports both models equivalently. The goal of this proposal is to determine the role of p27KIP1 in the cell cycle with reference to these two models. In particular, we will i) examine the effects of modulating p27KIP1 expression, both positively and negatively, on G1 progression, ii) we will determine the regulation of p27KIP1 both transcriptionally and translationally, and iii) ultimately determine the proteins that interact with P27KIP1 to modulate its functions during cellular proliferation. The expression of the cyclin E associated kinase is rate-limiting for G1 progression and also essential for progression of embryonic cells into S-phase. In addition, cyclin E mutations occur frequently in breast cancer cell lines, suggesting that inappropriate activation of cyclin E- associated kinases may be part of the tumorigenic process. p27KIP1 regulates the expression of the cyclin E-associated kinase by physically interacting with this kinase and preventing its activation. Consequently, it may be that mutation of cyclin E, in breast cancer cell lines, allows it to escape from growth regulation by p27KIP1. To address this we first need to understand both the role of p27KIP1 in cell proliferation, and how p27KIP1 is regulated during cell proliferation. These are the goals of this project, and the significance may be in gaining a better understanding of the tumorigenic process in tumors that have inappropriately activated cyclin E.
|
0.907 |
1996 — 2003 |
Koff, Andrew |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Regulation of P27 and Its Role in G1 Progression @ Sloan-Kettering Institute For Cancer Res
cyclin dependent kinase; cell cycle proteins; protein degradation; cell growth regulation; enzyme inhibitors; cyclins; protein structure function; posttranslational modifications; ubiquitin; enzyme activity; gene targeting; genetically modified animals; laboratory mouse;
|
0.907 |
2001 — 2005 |
Koff, Andrew |
R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
P27kip1 Expression, a Prognostic Indicator==But Why? @ Sloan-Kettering Institute For Cancer Res
The goal of this proposal is to understand why the loss of p27kip1 expression is a strong prognostic indicator for tumor development in many types of human cancer. This proposal examines two alternative hypotheses: First, that the loss of p27 may accelerate cell proliferation making the cell refractory to the negative growth influences of the surrounding cells; or second, that the loss of p27 may eliminate oncogene-induced apoptosis by "desensitizing" the cell to negative growth regulatory signals. In Aim 1, these two models will be examined in the development of pituitary tumors in Rb+/- and Rb+/-;p27-/- mice. Aim 2 will investigate the relationship between p27-deficiency and p53-mdm2-Arf induced apoptosis in the pituitary tumor mouse model, and in human breast and prostate tumor samples. Aim 3 will characterize the growth, apoptosis and transformation properties of mouse embryonic fibroblasts derived from Rb-/-;p27-/- embryos. A 4th Aim is proposed in the supplementary information that is based on the recent finding of Adenocarcinomas in p107+/-;p130-/-;p27-/- mice. This section will extend the analysis of Rb+/-;p27-/- mice to other pocket protein/p27 combinations to determine how loss of p27 modulates their tumor suppressor properties.
|
0.907 |